XHKG
2289
Market cap75mUSD
Sep 09, Last price
5.50HKD
Name
Charmacy Pharmaceutical Co Ltd
Chart & performance
P/E
10.95
P/S
0.12
EPS
0.43
Div yield, %
8.89%
Shrs. gr., 5y
—
Rev. gr., 5y
1.90%
Revenues
4.38b
-1.15%
Net income
46m
-13.16%
CFO
271m
+155.47%
Dividend
May 27, 20260.34353 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Charmacy Pharmaceutical Co., Ltd. serves as a prominent distributor of pharmaceutical products across the People's Republic of China. The company's comprehensive portfolio includes Western medications, traditional Chinese patent medicines, and various healthcare items, along with associated advisory services. These are supplied to both wholesale distributors and retail pharmacies. Furthermore, Charmacy operates "Charmacy e-Medicine," its proprietary B2B digital platform, which enables clients to efficiently place orders, make inquiries, and process payments online. Founded in 1984, the firm maintains its headquarters in Shantou, PRC. It was formerly known as Chuangmei Pharmaceutical Co., Ltd. until its official renaming to Charmacy Pharmaceutical Co., Ltd. in July 2016.
Key people
Jingbin Yan
Non-Executive Chairman of the Board · since 2023
Chuanglong Yao
Chief Executive Officer, Executive Vice Chairman of the Board · since 2023
Yuyan Zheng
Chief Marketing Officer, Vice President, Executive Director · since 2015
Hanzi Zhang
Finance Director - Person-in-Charge of Finance, Executive Director · since 2022
Zhijie Lin
Vice Logistics Officer · since 2007
Joint Company Secretary · since 2022
Jiexi Yao
Joint Company Secretary · since 2022
Zhen Fu
Non-Executive Director · since 2020
Fei Xu
Non-Executive Director · since 2023
Jian Guan
Non-Executive Independent Director · since 2015
Hanguo Li
Non-Executive Independent Director · since 2023
Chi Wai Wan
Non-Executive Independent Director · since 2015
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||